Introduction Acquired resistance to endocrine therapy (ET) remains a big challenge in the
management of metastatic breast cancer (MBC). A novel therapeutic agent, histone …

CCND1 is located on 11q13. Increased CCND1 copy number (CN) in breast cancer (BC) is
associated with high histopathological grade, high proliferation, and Luminal B subtype. In …

Simple Summary Low-grade serous ovarian cancer is a rare type of ovarian cancer that
usually has an indolent growth and affects younger women. It has markers that suggest it …

Endocrine resistance is a major challenge for breast cancer therapy. To identify the genes
pivotal for endocrine-resistance progression, we screened five datasets and found 7 …

Even though tamoxifen has significantly improved the survival of estrogen receptor positive
(ER+) mammary carcinoma (MC) patients, the development of drug resistance with …

Background Estrogen plays a crucial role in the tumorigenesis of breast cancer (BC), and
epigenetic modification by SUMOylation is essential for cancer development. However, the …

Endocrine resistance is a crucial challenge in estrogen receptor alpha (ERα)-positive breast
cancer (BCa). Aberrant alteration in modulation of E2/ERα signaling pathway has emerged …

Endocrine therapy (ET) is a well-validated strategy for estrogen receptor α positive (ERα+)
breast cancer therapy. Despite the clinical success of current standard of care (SoC) …

Background and objective: Many classification tasks in translational bioinformatics and
genomics are characterized by the high dimensionality of potential features and unbalanced …

An imbalance in estrogen signaling is a critical event in breast tumorigenesis. The majority
of breast cancers (BCs) are hormone-sensitive; they majorly express the estrogen receptor …